Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
TCRX
#3154
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
-3.64%
Monthly Change
-4.50%
6 month change
-43.32%
Year Change
-48.29%
Previous Close
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Volume
6
Markets
US Stock Market
Healthcare
TCRX
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2021
2022
2023
2024
TTM
Cash from operating activities
48.68 M
66.5 M
61.36 M
110.82 M
130.73 M
Cash from investing activities
9.94 M
4.22 M
60.76 M
52.61 M
67.25 M
Cash from financing activities
189.67 M
29.36 M
135.44 M
208.76 M
46.1 M
Free cash flow
38.74 M
62.28 M
58.21 M
107 M
125.61 M
News
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Tscan Therapeutics earnings beat by $0.06, revenue topped estimates
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates